Last reviewed · How we verify
Xermelo
At a glance
| Generic name | Xermelo |
|---|---|
| Also known as | Telotristat ethyl |
| Sponsor | TerSera Therapeutics LLC |
| Target | Tryptophan 5-hydroxylase 1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Diarrhea
Common side effects
- Nausea
- Headache
- Increased gamma-glutamyl-transferase (GGT)
- Depression
- Peripheral edema
- Flatulence
- Decreased appetite
- Pyrexia
- Abdominal pain
- Constipation
- Increased alkaline phosphatase
- Increased alanine aminotransferase
Serious adverse events
- Fecaloma
Key clinical trials
- Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor (PHASE3)
- Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer (PHASE2)
- AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm (PHASE2)
- Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
- Telotristat With Lutathera in Neuroendocrine Tumors (PHASE2)
- A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer (PHASE2)
- Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (PHASE2)
- Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |